Table 3.
Author, y | Primary LTx | Age (mo) | Pre-LTx chemo | Pre-LTx chemo cycles | Post-LTx chemo cycles | Post-LTx chemo |
---|---|---|---|---|---|---|
Schluckebier D, 2016 | 1 | 120 | Ifosfamide, vincristine, dactinomycin | 4 | 9 | Ifosfamide, vincristine, dactinomycin |
Shi Y, 2017 | 10 | 108 | NA | NA | NA | NA |
Techavichit P, 2016 | 1 | 264 | Ifosfamide doxorubicin | 5 | None | None |
Walther, 2014 | 1 | 156 | Ifosfamide doxorubicin | 6 | 4 | Vincristine, actinomycin D, cyclophosphamide |
Walther, 2014 | 1 | 132 | Ifosfamide doxorubicin. | 5 | 1 | Ifosfamide |
Ismail, 2013 | 1 | 4 | Cislplatin doxorubicin | 2 | NA | Cyclophosphamide, doxorubicin vincristine |
Rohan V, 2014 | 2 | 32 | NA | NA | NA | NA |
Chen LE, 2006 | 1 | 73 | Cisplatin, adriamycin, vincristine, Ifosfamide | 4 | None | None |
Chen LE, 2006 | 1 | 60 | Cisplatin, adriamycin, vincristine | 1 | None | None |
Okajima H, 2009 | 1 | 180 | Vincristine, actinomycin cyclophosphamide | Stopped early: side effects | NA | Vincristine, actinomycin, cyclophosphamide |
Dower NA, 2000 | 1 | 72 | Ifosfamide, carboplatin, etopiside | 2 | None | None |
Khan Z, 2017 | 1 | 252 | Ifosfamide doxorubicin | 5 | None | None |
Dhanasekaran R, 2012 | 1 | 648 | Adriamycin ifosfamide dacarbacine | 10 mo | None | None |
LTx, liver transplant; NA, data not available; none, did not have chemotherapy.